Physical presence of nor-binaltorphimine in mouse brain over 21 days after a single administration corresponds to its long-lasting antagonistic effect on κ-opioid receptors

J Pharmacol Exp Ther. 2013 Sep;346(3):545-54. doi: 10.1124/jpet.113.206086. Epub 2013 Jul 12.

Abstract

In the mouse 55°C warm-water tail-withdrawal assay, a single administration of nor-binaltorphimine (nor-BNI; 10 mg/kg i.p.) antagonized κ-opioid receptor (KOR) agonist-induced antinociception up to 14 days, whereas naloxone (10 mg/kg i.p.)-mediated antagonism lasted less than 1 day. In saturation binding experiments, mouse brain membranes isolated and washed 1 or 7 (but not 14) days after nor-BNI administration demonstrated a significant time-dependent decrease in maximal KOR agonist [(3)H]U69,593 binding. To determine whether brain concentrations of nor-BNI were sufficient to explain the antagonism of KOR-mediated antinociception, mouse blood and perfused brain were harvested at time points ranging from 30 minutes to 21 days after a single administration and analyzed for the presence of nor-BNI using liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS). Nor-BNI was detected in the perfused brain homogenate up to 21 days after administration (30 nmol i.c.v. or 10 mg/kg i.p.). Subsequent experiments in which nor-BNI was administered at doses estimated from the amounts detected in the brain homogenates isolated from pretreated mice over time demonstrated significant antagonism of U50,488 antinociception in a manner consistent with the magnitude of observed KOR antagonism. The dose (1.4 nmol) approximating the lowest amount of nor-BNI detected in brain on day 14 did not antagonize U50,488-induced antinociception, consistent with the absence of U50,488 antagonism observed in vivo at this time point after pretreatment. Overall, the physical presence of nor-BNI in the mouse brain paralleled its in vivo pharmacological profile, suggesting physicochemical and pharmacokinetic properties of nor-BNI may contribute to the prolonged KOR antagonism.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Analgesics / metabolism
  • Analgesics / pharmacology
  • Animals
  • Benzeneacetamides / metabolism
  • Benzeneacetamides / pharmacology
  • Brain / metabolism*
  • Chromatography, High Pressure Liquid
  • Hot Temperature
  • Injections, Intraventricular
  • Membranes / drug effects
  • Membranes / metabolism
  • Mice
  • Mice, Inbred C57BL
  • Naloxone / pharmacokinetics
  • Naloxone / pharmacology
  • Naltrexone / analogs & derivatives*
  • Naltrexone / pharmacokinetics
  • Naltrexone / pharmacology
  • Narcotic Antagonists / pharmacokinetics
  • Narcotic Antagonists / pharmacology*
  • Pain Measurement / drug effects
  • Pyrrolidines / metabolism
  • Pyrrolidines / pharmacology
  • Receptors, Opioid, kappa / antagonists & inhibitors*
  • Reference Standards
  • Tandem Mass Spectrometry
  • Time Factors

Substances

  • Analgesics
  • Benzeneacetamides
  • Narcotic Antagonists
  • Pyrrolidines
  • Receptors, Opioid, kappa
  • Naloxone
  • norbinaltorphimine
  • Naltrexone
  • U 69593